Acute akathisia is one of the most under-recognized and clinically consequential adverse effects of dopamine-blocking medications, and it remains a frequent driver of antipsychotic nonadherence, treatment dropout, and (in some series) suicidal ideation. The syndrome is defined by a subjective sense of inner restlessness coupled with observable motor restlessness, usually appearing within hours to weeks of starting or increasing an offending agent. Akathisia sits within the DSM-5-TR category of medication-induced movement disorders, distinct from tardive and chronic forms, and is captured in ICD-11 under disorders due to substances or medications. The clinician's task is twofold: separate akathisia from psychotic agitation, anxiety, or restless legs, and then act on it, because patients rarely volunteer the symptom and often describe it in ways that invite the wrong intervention. The bottom line for the bedside: when a patient on a dopamine antagonist looks more agitated rather than less, suspect akathisia before adding another antipsychotic dose.

Acute akathisia is among the most common extrapyramidal side effects, with incidence shaped heavily by the offending agent, dose, and titration speed. Recognition rates depend on whether clinicians screen for it actively or wait for patient report.

Prevalence and incidence

• Acute akathisia occurs in roughly 20-35% of patients started on first-generation antipsychotics at standard doses, with higher rates on high-potency agents such as haloperidol and fluphenazine.^[1-2]
• Second-generation antipsychotics carry lower but clinically meaningful rates; pooled estimates from clinical trials place incidence at 10-15% across the class, with substantial variation by agent.^[3]
• Aripiprazole and lurasidone are consistently associated with higher akathisia rates than olanzapine, quetiapine, or clozapine in head-to-head data.^[3-4]
• Antiemetics with dopamine D2 antagonism (metoclopramide, prochlorperazine) account for a non-trivial share of cases seen in emergency settings.^[5]

Demographics and risk factors

• Female sex, middle age, and the presence of mood disorders are associated with higher reported incidence in clinical samples.^[1,6]
• Iron deficiency, even without anemia, has been linked to increased susceptibility, paralleling observations in restless legs syndrome.^[7]
• Rapid dose escalation and parenteral administration are stronger predictors than total daily dose.^[2,8]
• Prior akathisia, comorbid Parkinson disease, and concurrent SSRI or SNRI use raise risk.^[6,8]

The mechanism remains incompletely characterized, but the dominant model centers on dopaminergic blockade in mesocortical and nigrostriatal pathways with secondary effects on noradrenergic and serotonergic systems. Iron-dependent dopamine handling provides a plausible bridge to the restless legs literature.

Neurobiology

• D2 receptor antagonism in the Mesocortical pathway is the leading mechanistic hypothesis, supported by the dose-response relationship between D2 occupancy (above approximately 80%) and akathisia incidence on PET studies.^[10]
• Partial agonists such as aripiprazole produce akathisia despite lower net D2 antagonism, suggesting that intrinsic activity at presynaptic autoreceptors and downstream signaling matter beyond receptor occupancy alone.^[4,10]
• Noradrenergic hyperactivity is implicated by the partial efficacy of beta-blockers, particularly lipophilic agents that cross the blood-brain barrier.^[11]
• 5-HT2A and 5-HT2C antagonism may modulate risk; the relatively low akathisia profile of clozapine and quetiapine is consistent with this.^[12]

Genetics and biology

• No robust GWAS signal has emerged; candidate-gene studies implicating Catechol-O-methyltransferase (COMT) and dopamine receptor polymorphisms have not replicated consistently.^[13]
• Low serum ferritin and reduced brain iron stores have been reported in akathisia cohorts, mirroring restless legs syndrome and offering a testable mechanistic link.^[7]

Contributing pharmacology

• Rapid titration, parenteral loading, and high-potency D2 antagonists are the most consistent pharmacologic risk amplifiers.^[2,8]
• SSRIs and SNRIs can induce akathisia independent of antipsychotic exposure, likely via downstream serotonergic modulation of dopaminergic tone.^[14]
• Withdrawal of anticholinergics in a patient on an antipsychotic can unmask akathisia previously suppressed.^[15]

DSM-5-TR places medication-induced acute akathisia among the medication-induced movement disorders, requiring both subjective distress and observable motor restlessness developing in temporal relationship to a causative agent. The diagnosis is clinical; no laboratory test confirms it.

DSM-5-TR criteria

• Subjective complaints of restlessness, most often referred to the legs, accompanied by observed movements such as fidgeting, leg-crossing, rocking from foot to foot, pacing, or inability to sit or stand still.^[16]
• Symptoms develop within a few weeks of starting or raising the dose of a medication (most commonly an antipsychotic) or after reducing a medication used to treat extrapyramidal symptoms.^[16]
• The symptoms cause clinically significant distress or impairment and are not better explained by another mental disorder or medical condition.^[16]

Course modifiers

• Acute akathisia onsets within hours to days of exposure or dose increase and typically resolves with dose reduction or removal of the agent.^[16-17]
• Subacute (>6 weeks) and chronic (>3 months) forms exist and behave differently with respect to treatment response.^[17]
• Withdrawal akathisia appears on dose reduction or discontinuation of a chronic antipsychotic, usually within 6 weeks, and remits over weeks to months.^[17]
• Tardive akathisia, with onset after months to years of exposure and persistence after discontinuation, is categorized separately and overlaps mechanistically with tardive dyskinesia.^[17]

ICD-11 placement

• ICD-11 classifies medication-induced akathisia under disorders due to substances or medications (6C4Y / 6E60 family), preserving the acute / tardive distinction but without DSM-5-TR's discrete numerical thresholds.^[18]

The hallmark is a mismatch between what the patient describes and what the clinician sees. Patients often have trouble naming the experience; the examiner must elicit it actively and watch the lower body.

Subjective features

• Inner restlessness, an urge to move, a feeling of "crawling out of my skin," or a sense of dread that drives movement rather than follows it.^[1,17]
• Symptoms are typically worse at rest and partially relieved by movement, though relief is usually incomplete.^[17]
• Patients frequently report worsening anxiety, dysphoria, or irritability and may describe a sense that the medication is making them "feel worse."^[6,19]

Objective features

• Rocking from foot to foot while standing, marching in place, repeatedly crossing and uncrossing the legs while seated, pacing, and inability to remain still for a clinical interview.^[9,17]
• Movements tend to be semi-purposeful and stereotyped rather than choreiform or tic-like.^[17]
• Severe cases may show agitation, refusal to sit, sleep disruption, and aggressive outbursts.^[19]

Course

• Onset within hours to a few weeks of starting or up-titrating an offending agent; depot antipsychotics may produce delayed peaks aligned with pharmacokinetics.^[2,17]
• Symptoms wax and wane over the day and are often worse in the evening.^[1]
• Untreated, acute akathisia drives nonadherence, premature discontinuation, and rotation through agents that may share the offending class.^[6,8]

Red flags

• New suicidal ideation in a patient recently started on or up-titrated on a dopamine antagonist should prompt explicit akathisia screening.^[19-20]
• Worsening "agitation" after a stat dose of an antipsychotic in the emergency department, particularly after IM haloperidol, should be presumed to be akathisia until shown otherwise.^[5,19]

The differential is where most misdiagnoses occur, because akathisia mimics, and is mimicked by, the very conditions for which the offending drug was prescribed. Anchor the diagnosis to the temporal relationship and the lower-body restlessness.

Psychiatric mimics

• Psychotic agitation: agitation is typically driven by content of thought, lacks the urge-to-move quality, and does not localize to the legs; it should improve, not worsen, with adequate antipsychotic dosing.^[19]
• Anxiety and panic: anxious patients can fidget, but the inner restlessness of akathisia is not relieved by reassurance, and there is usually no autonomic surge or cognitive content of catastrophe.^[1,6]
• Agitated depression and mixed mood states: psychomotor activation can mimic akathisia, but it precedes drug exposure and does not localize to the legs.^[6]
• Stimulant-induced restlessness: history of recent stimulant initiation or misuse should be sought before attributing symptoms to a D2 blocker.^[14]

Neurologic and medical mimics

• Restless legs syndrome (RLS): worse at night, relieved more completely by movement, often associated with periodic limb movements of sleep; a personal or family history clarifies the picture.^[7]
• Parkinson disease and parkinsonism: bradykinesia and rigidity should dominate, not restlessness, though akathisia can coexist.^[15]
• Tardive dyskinesia: choreiform orofacial and limb movements without the subjective urge to move.^[17]
• Hyperthyroidism, pheochromocytoma, and hypoglycemia can produce restlessness with autonomic signs that should not appear in akathisia.^[6]

Substance-related mimics

• Stimulant intoxication (cocaine, amphetamines, caffeine excess) and serotonin toxicity can produce motor restlessness; serotonin toxicity adds clonus, hyperreflexia, and autonomic instability.^[14]
• Alcohol or benzodiazepine withdrawal restlessness is accompanied by tremor, diaphoresis, and tachycardia.^[5]

Assessment is bedside-driven: a focused history of recent medication changes, a brief structured rating, and a short observation period under standardized conditions. Imaging and labs are for excluding mimics, not confirming akathisia.

History, mandatory elements

• A precise timeline of every dopamine-blocking agent (antipsychotic, antiemetic, tetrabenazine and analogs) initiated or up-titrated in the prior 6 weeks, including depot dates.^[2,17]
• Concomitant SSRI / SNRI starts, anticholinergic discontinuations, and changes to dopaminergic medications in Parkinson disease.^[14-15]
• Patient's own language for the symptom ("can't sit still," "feel wired," "want to jump out of my skin") and any associated suicidal ideation.^[19-20]

Examination

• Observe the patient seated for at least 2 minutes and standing with feet together for 30-60 seconds; record any rocking, marching, or shifting.^[9]
• Look for coexisting parkinsonism (rigidity, bradykinesia, cogwheeling) and tardive movements (orofacial chorea, choreoathetoid limb movements).^[15,17]
• Vital signs and a focused neurologic exam to exclude autonomic causes and identify Parkinson disease, thyrotoxicosis, or substance intoxication.^[6]

Rating scales

• The BARS is the standard, comprising objective, subjective awareness, subjective distress, and global clinical assessment items; a global score ≥2 supports the diagnosis.^[9]
• The HAS and Prince Henry Akathisia Scale are alternatives used in research settings.^[1]
• Repeat ratings before and after intervention, not just at baseline.^[9]

Labs and imaging

• Ferritin and a basic metabolic panel are reasonable to exclude iron deficiency and electrolyte mimics; routine MRI is not indicated.^[7]
• TSH if symptoms are atypical or autonomic features suggest thyrotoxicosis.^[6]
• Toxicology screening when stimulant or serotonergic substance use is plausible.^[14]

What NOT to order

• Routine neuroimaging, EEG, or genetic testing are not first-line; they are reserved for atypical presentations or refractory cases with focal neurologic findings.^[15]

The first move is to address the offending agent (reduce, switch, or stop), and the second is symptomatic suppression while the offender is being adjusted. Evidence is best for beta-blockers and benzodiazepines in the short term; antimuscarinics work when parkinsonism coexists.

General principles

• Reassess the indication and dose of every dopamine-blocking agent; the lowest effective dose of the highest-tolerability agent is the durable answer.^[8,21]
• Slow titration and avoiding parenteral loading reduce incidence and severity in the first place.^[2,8]
• Discuss the diagnosis with the patient; misattribution to "worsening illness" drives nonadherence and morale loss.^[6,19]

Pharmacotherapy

• First-line is reducing the offending agent or switching to a lower-akathisia-risk antipsychotic when clinically feasible.^[21-22]
• propranolol 10-30 mg PO TID, a lipophilic non-selective beta-blocker, is the most studied symptomatic agent, with moderate-quality evidence for short-term benefit.^[11,21]
• lorazepam 0.5-2 mg PO BID-TID or clonazepam 0.5-2 mg PO BID provide symptomatic relief, particularly when anxiety and sleep disruption coexist; limit duration to avoid dependence.^[21,23]
• benztropine 1-2 mg PO BID or trihexyphenidyl 2-5 mg PO TID are useful when parkinsonism coexists; benefit in pure akathisia is smaller and inconsistent.^[15,21]
• mirtazapine 15 mg PO QHS has moderate-quality evidence from small randomized trials, likely via 5-HT2A antagonism.^[12,24]
• cyproheptadine 8-16 mg PO QD, another 5-HT2 antagonist, has limited supportive evidence in refractory cases.^[12]
• Switching to a lower-risk antipsychotic (often clozapine, quetiapine, or olanzapine) is appropriate when symptoms persist despite optimization.^[3,22]

Psychotherapy

• Psychotherapy is not a primary intervention; psychoeducation about the syndrome, expected timeline, and management plan is essential and reduces distress and nonadherence.^[6,19]

Neuromodulation

• No established role for ECT, rTMS, or other neuromodulation in acute akathisia; case reports are insufficient to recommend.^[21]

Adjunctive

• Iron repletion may help patients with low ferritin (<50 ng/mL), extrapolating from RLS evidence; high-quality data in akathisia are lacking.^[7]
• Sleep hygiene, reduced caffeine, and avoidance of evening stimulants are sensible adjuncts.^[6]
• Vitamin B6 (pyridoxine) at high doses (600-1200 mg/day) has limited supportive evidence and is sometimes trialed.^[25]

The harms picture in acute akathisia is dominated less by the syndrome's direct physiology than by what untreated symptoms drive patients to do, and by the side effects of the agents used to treat it. The evidence base is also older and smaller than the clinical importance of the topic warrants.

Harms of untreated akathisia

• Antipsychotic nonadherence and premature discontinuation, with downstream relapse risk.^[6,8]
• Suicidal ideation and completed suicide have been linked to severe akathisia in observational data, though causal inference is constrained by confounding by indication.^[19-20]
• Aggression, agitation, and emergency department revisits, often producing iatrogenic up-dosing of the offending agent.^[5,19]

Harms of pharmacotherapy

• Propranolol: bradycardia, hypotension, bronchospasm, fatigue, and masking of hypoglycemia.^[11]
• Benzodiazepines: sedation, falls in older adults, cognitive effects, and dependence with chronic use.^[23]
• Antimuscarinics: dry mouth, urinary retention, constipation, blurred vision, and cognitive impairment, particularly in older adults.^[15]
• Mirtazapine: sedation, weight gain, and rare hematologic effects.^[24]

Limitations of the evidence base

• Most pharmacotherapy trials are small (n<60), short (2-6 weeks), and conducted in inpatient samples that may not generalize.^[21,24]
• Outcome measures rely on the BARS, which captures observable and subjective dimensions but is rater-dependent.^[9]
• Few trials directly compare contemporary second-generation antipsychotics for akathisia incidence.^[3]
• Long-term outcomes, including durability of response and relapse after discontinuation of symptomatic therapy, are under-studied.^[21]

Risk-benefit calculations shift across the lifespan and comorbidity profile. Recognition is harder in patients who cannot easily articulate inner restlessness.

Pediatric

• Children and adolescents on antipsychotics, particularly for aggression or autism-related irritability, develop akathisia at rates comparable to adults; aripiprazole and risperidone are common offenders.^[26]
• Symptoms may present as worsening behavioral dysregulation; clinicians should ask the child to stand still and observe the lower body.^[26]

Geriatric

• Older adults are more sensitive to D2 blockade and to anticholinergic and benzodiazepine adverse effects; preference is for the lowest effective dose and for propranolol or mirtazapine over antimuscarinics or benzodiazepines.^[15,21]
• Antiemetics (metoclopramide, prochlorperazine) are a frequently overlooked source of akathisia in hospitalized older patients.^[5]

Perinatal

• Antipsychotic-induced akathisia in pregnancy is managed primarily by dose adjustment; propranolol is generally compatible with pregnancy and lactation when symptomatic treatment is needed.^[27]
• Maternal akathisia warrants treatment because severe symptoms can compromise prenatal care adherence and maternal wellbeing.^[27]

Comorbid medical illness

• Patients with Parkinson disease may develop akathisia from dopamine-blocking antiemetics; safer alternatives include ondansetron or domperidone where available.^[15]
• Cardiac patients on beta-blockers for cardiovascular indications may already have partial coverage; coordinate with cardiology before adding additional beta-blockade.^[11]

Comorbid substance use

• Stimulant use complicates assessment and treatment; akathisia and stimulant restlessness can coexist, and benzodiazepine use carries higher misuse risk in this group.^[14,23]

Cultural considerations

• Patients from cultural backgrounds where somatic descriptors predominate may describe akathisia as "nerves" or in idioms of distress; structured assessment reduces missed diagnoses.^[6]

Most acute akathisia resolves once the offending agent is reduced or switched and symptomatic therapy is added. A meaningful minority transitions to chronic or tardive forms, particularly with continued exposure.

Natural history

• Acute akathisia typically improves within days of dose reduction and remits within weeks of switching to a lower-risk agent.^[17,21]
• Symptomatic pharmacotherapy with propranolol or mirtazapine produces measurable benefit within 1-3 days in responders.^[11,24]
• A subset of patients develops chronic or tardive akathisia, which is less responsive to dose reduction and may persist after discontinuation.^[17]

Functional outcome

• Untreated akathisia roughly doubles the risk of antipsychotic discontinuation within the first 3 months of treatment in observational cohorts.^[6,8]
• Recognition and active treatment improve adherence and reduce inpatient revisits.^[6]

Mortality

• Severe akathisia has been associated with increased suicidal ideation and, in older case series, completed suicide; rigorous incidence figures are not available.^[19-20]
• No direct mortality from akathisia itself has been established beyond behavioral consequences.^[20]

Acute akathisia is a not-uncommon iatrogenic emergency, particularly after parenteral antipsychotic administration. The error to avoid is reflexively giving more antipsychotic to a patient who is now more agitated than before.

Acute management

• Suspect akathisia in any patient whose agitation worsens after IM haloperidol or after antiemetic D2 antagonists in the emergency department.^[5,19]
• First-line acute treatment is parenteral or oral lorazepam or diphenhydramine; benztropine 1-2 mg IM is appropriate when parkinsonism coexists.^[5,21]
• Stop further dosing of the offending agent; review the indication before re-dosing.^[5,19]

Hospitalization considerations

• Severe akathisia with suicidal ideation, refusal of medication, or aggression may warrant admission for monitored medication adjustment.^[19-20]
• Document the diagnosis explicitly in the chart to prevent reflex re-dosing on the next shift.^[19]

Safety counseling

• Advise patients and families that worsening restlessness or new suicidal thoughts in the days after a medication change should prompt urgent contact.^[19-20]
• Provide a written plan describing which symptoms warrant call, urgent visit, or emergency department evaluation.^[6]

Several aspects of akathisia management rest on modest evidence and continue to generate debate among clinicians and guideline writers.

Pharmacologic first line

• Propranolol is the most cited first-line agent, yet the supporting trials are small, decades old, and used heterogeneous outcome measures; some recent reviews question its primacy over mirtazapine or 5-HT2A antagonism strategies.^[11,21,24]
• Mirtazapine 15 mg at bedtime showed superiority to placebo and non-inferiority to propranolol in a small randomized trial, but replication is limited and the dose overlaps with sedating antidepressant use, complicating attribution.^[24]
• Benzodiazepines are widely prescribed but the controlled evidence is thin, and habitual use creates dependence and falls risk that outweigh short-term benefit.^[23]

Akathisia and suicide

• The association between akathisia and suicidal behavior is reported across multiple cohorts, but causality remains contested because severe akathisia clusters with severe primary illness, high antipsychotic doses, and prior suicide attempts.^[19-20]
• Regulatory labels for several antipsychotics list akathisia as a risk factor for suicidality without quantifying the independent contribution.^[20]

SSRI- and SNRI-induced akathisia

• Whether antidepressant-induced akathisia is mechanistically identical to dopamine-blocker akathisia is unsettled; serotonergic modulation of mesocortical dopamine is one proposed mechanism, but the phenotype is often milder and harder to separate from activation or agitation.^[14]
• The clinical implication, that early SSRI-related restlessness can mimic worsening depression and trigger dose escalation, is widely accepted even where the mechanism is not.^[14]

Chronic and tardive akathisia

• The boundary between persistent acute akathisia and tardive akathisia is operationally defined by duration on a stable dose, but the underlying biology may differ; tardive forms respond poorly to anticholinergics and may worsen with them.^[1,6]
• VMAT2 inhibitors (valbenazine, deutetrabenazine) are approved for tardive dyskinesia and have been studied in tardive akathisia with mixed results; their role in acute akathisia is not established.^[21]

Anticholinergic use

• Older guidance lumped akathisia with other extrapyramidal syndromes and recommended anticholinergics; current evidence suggests anticholinergics are less effective for akathisia than for parkinsonism and dystonia, and add cognitive and anticholinergic burden.^[15,21]
• Where parkinsonism and akathisia coexist, a trial of an anticholinergic remains reasonable, but it should not be the default for isolated akathisia.^[15]

• Acute akathisia is defined by subjective inner restlessness plus observable motor restlessness, appearing within hours to weeks of starting or up-titrating a dopamine-blocking agent.^[16]
• High-potency first-generation antipsychotics (haloperidol, fluphenazine) carry the highest risk; among second-generation agents, aripiprazole, lurasidone, and cariprazine are most implicated.^[3-4,8]
• The Barnes Akathisia Rating Scale is the standard instrument; a global score of 2 or higher indicates clinically significant akathisia warranting intervention.^[9]
• Akathisia is an independent risk factor for antipsychotic nonadherence and is associated with suicidal ideation and behavior.^[19-20]
• First-line management is reduction of the offending dose or switching to a lower-risk agent such as quetiapine, olanzapine, or clozapine.^[21-22]
• Propranolol 30 to 90 mg per day in divided doses (typically 10 to 30 mg TID) is the most commonly recommended adjunct; contraindicated in asthma and bradyarrhythmia.^[11,21]
• Mirtazapine 15 mg at bedtime is an evidence-supported alternative, particularly useful when beta-blockers are contraindicated.^[24]
• Anticholinergics are less effective for akathisia than for parkinsonism or dystonia and should not be the first adjunct for isolated akathisia.^[15,21]
• Metoclopramide and prochlorperazine are common nonpsychiatric causes of acute akathisia in emergency department and postoperative settings.^[5]
• Restless legs syndrome is distinguished by circadian worsening at night, urge to move limbs specifically, and relief with movement; akathisia lacks the circadian pattern and involves whole-body restlessness.^[7]
• DSM-5-TR classifies medication-induced acute akathisia under medication-induced movement disorders, separate from tardive and chronic forms.^[16]
• Akathisia masquerading as worsening psychosis can lead to inappropriate antipsychotic dose increases, worsening the syndrome; recognition is the key safety step.^[1-2]
• Iron deficiency lowers the threshold for akathisia and restless legs; check ferritin in refractory cases.^[7]
• Pediatric and adolescent patients on antipsychotics for irritability or psychosis are at elevated risk; akathisia in this group is often misread as behavioral worsening.^[26]

No external funding. No conflicts of interest declared. Peer-review status: pending.